Fig 1.
PUQE-24*-questionnaire used in prospective cohort validation study of HG^ versus healthy pregnant women.
*Pregnancy-Unique Quantification of Emesis and nausea. ^Hyperemesis Gravidarum.
Fig 2.
Outline of enrolment in prospective cohort study validating Norwegian PUQE-24* in HG^ patients (n = 38) and healthy pregnant women (n = 31).
*Pregnancy-Unique Quantification of Emesis and nausea. ^Hyperemesis Gravidarum.
Table 1.
Clinical information from patients hospitalized for HG* and healthy pregnant women.
Table 2.
PUQE-24* and Quality of Life scoring in prospective cohort validation study of HG^ and healthy pregnant women.
Fig 3.
PUQE-24*-score in HG^ patients (n = 38) at admission, healthy pregnant women (n = 31) and HG^ patients (n = 35) at discharge.
*Pregnancy-Unique Quantification of Emesis and nausea. ^Hyperemesis Gravidarum.
Fig 4.
PUQE-24*-score in relation to gestational length for HG^ patients (n = 38) and controls (n = 31).
*Pregnancy-Unique Quantification of Emesis and nausea. ^Hyperemesis Gravidarum.
Table 3.
Quality of Life (QOL) score, energy intake and weight change from preconception to inclusion compared to PUQE-24*-score severity.
Table 4.
PUQE*-24-scores from women with Hyperemesis Gravidarum (HG) at admission and discharge from hospital.
Table 5.
Nutritional intake during 24 hours from patients hospitalized due to Hyperemesis Gravidarum versus healthy pregnant women.